TP53 and diffuse large B-cell lymphoma: The observed heterogeneity in p53 IHC’s prognostic performance across studies likely reflects two key factors: inherent biological variability among DLBCL patients and interlaboratory discrepancies in staining protocols and interpretation criteria, particularly in cutoff value determination.